Background Image
Table of Contents Table of Contents
Previous Page  158 / 1498 Next Page
Information
Show Menu
Previous Page 158 / 1498 Next Page
Page Background

0

25

50

75

100

Cumulative Percentage

90

Y-ibritumomab

Control

207

202

110

149

N

F

PFS From Time of Randomization (months)

Overall PFS For Treatment Groups

90

Y-ibritumomab: n = 207

Median PFS: 49.3 mo

Control: n = 202

Median PFS: 12.6 mo

7-year overall PFS 23% in control arm compared with 47% in

90

Y-ibritumomab arm

HR = 2.09 (95% CI: 1.63 – 2.67);

P

< 0.001

90

Y-ibritumomab

Control

207

143

86

102

63

89

48

25

14

At risk:

202

0

21

42

63

84